Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M. & Ross, J. S. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. J. Am. Med. Assoc. 311, 368 (2014).
2. European Medicines Agency. Clinical trials on human medicines. https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines (accessed 3 August 2023).
3. Piskin, D. et al. Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Ann. Rheum. Dis. 81, 1203–1205 (2022).
4. Di Donato, G., d’Angelo, D. M., Breda, L. & Chiarelli, F. Monogenic autoinflammatory diseases: state of the art and future perspectives. Int. J. Mol. Sci. 22, 6360 (2021).
5. Romano, M. et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann. Rheum. Dis. 81, 907–921 (2022).